Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:

Testing for targetable biomarkersTalking with patients about biomarker testingFrontline therapy for EGFR-positive NSCLCResistance to front-line osimertinibTreatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecanHER3 protein testingPathology considerationsNursing considerationsInterdisciplinary communication

Presenters:

Conor Ernst Steuer, MD
Assistant Professor
Department of Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Frank Schneider, MD
Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Director, Cancer Tissue and Pathology Shared Resource
Winship Cancer Institute
Emory University
Atlanta, Georgia

Elise Hitron, MSN, FNP-C
Adjunct Instructor
School of Nursing
Phase I Clinical Trials Nurse Practitioner
Winship Cancer Institute
Emory University
Atlanta, Georgia

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:
https://bit.ly/3G32Jkm